VIA
REGN icon

Vident Investment Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Vident Investment Advisory’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,634
Closed -$11.2M – 806
2023
Q2 		$11.2M Sell
15,634
-4,650
-23% -$3.59M 0.39% 60
2023
Q1 		$16.7M Buy
20,284
+1,679
+9% +$1.27M 0.54% 31
2022
Q4 		$13.4M Buy
18,605
+9,755
+110% +$7.2M 0.51% 32
2022
Q3 		$5.79M Sell
8,850
-9,897
-53% -$6.23M 0.19% 147
2022
Q2 		$11.1M Buy
18,747
+9,768
+109% +$6.35M 0.33% 66
2022
Q1 		$6.27M Sell
8,979
-4,634
-34% -$2.93M 0.16% 146
2021
Q4 		$8.6M Sell
13,613
-2,355
-15% -$1.45M 0.22% 89
2021
Q3 		$9.66M Buy
15,968
+3,100
+24% +$1.92M 0.29% 66
2021
Q2 		$7.19M Sell
12,868
-1,640
-11% -$831K 0.22% 78
2021
Q1 		$6.86M Buy
14,508
+4,834
+50% +$2.35M 0.23% 76
2020
Q4 		$4.67M Buy
9,674
+1,419
+17% +$766K 0.19% 90
2020
Q3 		$4.62M Buy
8,255
+493
+6% +$299K 0.23% 87
2020
Q2 		$4.84M Buy
7,762
+10
+0.1% +$5.68K 0.25% 78
2020
Q1 		$3.79M Buy
7,752
+3,276
+73% +$1.35M 0.25% 77
2019
Q4 		$1.68M Sell
4,476
-443
-9% -$149K 0.1% 301
2019
Q3 		$1.36M Sell
4,919
-169
-3% -$50K 0.12% 129
2019
Q2 		$1.59M Buy
5,088
+655
+15% +$218K 0.13% 110
2019
Q1 		$1.82M Sell
4,433
-88
-2% -$36.2K 0.1% 309
2018
Q4 		$1.69M Buy
4,521
+3,209
+245% +$1.17M 0.09% 293
2018
Q3 		$530K Sell
1,312
-402
-23% -$153K 0.02% 670
2018
Q2 		$591K Sell
1,714
-279
-14% -$87.3K 0.02% 598
2018
Q1 		$637K Sell
1,993
-175
-8% -$60.9K 0.03% 512
2017
Q4 		$815K Buy
2,168
+1,720
+384% +$697K 0.04% 412
2017
Q3 		$200K Buy
+448
New +$213K 0.01% 716
2015
Q3 		– Sell
-10
Closed -$5K – 1136
2015
Q2 		$5K Buy
+10
New +$4.88K ﹤0.01% 1016

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vident Investment Advisory's REGN Position: Q3 2023 in Review

Vident Investment Advisory sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 15,634 shares — an estimated $11.2M sold.

Vident Investment Advisory first reported a position in REGN in Q2 2015 and held it in 25 quarters. The position peaked at $16.7M in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Vident Investment Advisory reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 15,634 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $11.2M.
  • Vident Investment Advisory first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 25 quarters.
  • Vident Investment Advisory's Regeneron Pharmaceuticals position peaked at $16.7M in Q1 2023.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.